The Milken Institute, one of two collaborators with 23andMe’s Depression and Bipolar Study, began the survey last year and found that 89 percent of those with depression or bipolar disorder or both said there was a need for better treatments and care.

23andMe's Head of Therapeutics Kenneth Hillan, M.B., Ch.B., discussed his career and the vision for 23andMe's work in therapeutics

An update on recruitment for the Fox Insights Parkinson's research initiative.

23andMe's Parkinson's research community manager, Paul Cannon shares his experience with Deep Brain Stimulation to treat his Parkinson's symptoms.

In honor of Mental Health Awareness Month, we’re taking a moment to highlight how anyone can be there for the people in their lives by starting a conversation about mental...

New data on declining fertility in the United States points to a need for new efforts to better understand improving fertility outcomes in women who wait to have their children.

As part of a broad collaboration with the Michael J. Fox Foundation, 23andMe is inviting participants in its Parkinson's Research community to participate in a new initiative called Fox Insights to make data broadly available to qualified researchers worldwide starting in 2018, with the goals of sparking innovation and discoveries around Parkinson’s disease.

Scientists at 23andMe and Genentech have identified 17 new genetic variants associated with Parkinson’s disease, almost doubling the total number of known risk variants for the condition, which gives scientists hints at potential new targets for drugs to treat the disease.

In collaboration with The Milken Institute and Lundbeck, 23andMe is launching a groundbreaking new study leveraging 23andMe’s unique research model to look at the genetics underlying depression and bipolar disorder.In...

With breathtaking speed, 23andMe and Celmatix have finished recruiting and enrolling participants in a groundbreaking study on fertility. Launched in February, the study aimed to enroll 4,500 women. It can...